Goldman Sachs starts MeiraGTx coverage with a USD 16 target for MeiraGTx stock

Published on 10/02/2026 at 00:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 321.43 million, up from USD 3.70 million. MeiraGTx stock had USD 987.2 million market value on October 1, 2026.

MGTX, KYG596651029, Illustration mit AI erstellt.

Goldman Sachs initiated coverage of MeiraGTx with a Neutral rating and a USD 16.00 price target on September 24, 2026, according to Markets Insider. MeiraGTx stock is being assessed against regulatory uncertainty surrounding botaretigene sparoparvovec, the company's lead gene therapy program.

Goldman sees regulatory uncertainty

The USD 16.00 target stands 50.09 percent above the USD 10.66 last Nasdaq price on October 1, 2026, calculated from the same currency. The Goldman Sachs view therefore places regulatory execution at the center of the valuation, rather than treating the clinical pipeline as a complete commercial business.

MeiraGTx develops gene therapies for serious diseases, including inherited retinal disorders, radiation-induced xerostomia and Parkinson's disease. The company says its platform combines targeted delivery, internal manufacturing and synthetic riboswitch technology, according to its investor-relations profile.

Second-quarter revenue jumps

MeiraGTx reported USD 321.43 million of revenue for the second quarter of 2026, up from USD 3.70 million in the second quarter of 2025, while net income reached USD 160.67 million compared with a USD 38.80 million loss a year earlier, according to StockTitan. The result included USD 204.60 million of license revenue and USD 104.90 million of related-party service revenue, making collaboration income a major part of the quarter.

Cash and cash equivalents stood at USD 143.17 million on June 30, 2026, while operating cash flow was negative USD 38.54 million in the second quarter. That contrast matters because the reported profit was driven by licensing and collaboration activity, while development programs continued to consume cash.

Stock sits below yearly high

MGTX was last at USD 10.66 on Nasdaq after hours on October 1, 2026, versus a USD 11.00 prior close and a minus 3.09 percent session change. The quote was 30.55 percent below the USD 15.35 52-week high and 61.03 percent above the USD 6.62 52-week low, while market capitalization stood at USD 987.2 million.